AMELIE is funded by the European Union’s Horizon 2020 research and innovation programme under the call for Better Health and care, economic growth and sustainable health systems (H2020-SC1-BHC-2018-2020). Our sister projects are those who were funded in the same call. We’re connected by our joint aim of developing therapies and treatments to tackle different health issues and improve the lives of people living with them.


Develop a stem cell therapy to repair brain injury related to preterm birth.

The brain injury in the premature born infant: stem cell regeneration research network, PREMSTEM, is a collective of world leading clinicians, researchers, stakeholder advocacy groups and an industrial partner with well-established experience in neonatology and drug development. On a global scale, around 15 million babies are born preterm every year (before the 37th week of gestation) and our research aims to create a new therapy to treat brain injury associated with being born too soon. There are currently no treatments available to repair this injury, which is known as encephalopathy of prematurity (EOP). We’re investigating the potential of stem cells taken from donated umbilical cord tissue to treat EOP with our research framed around three key questions: When should we give the stem cells? How many should we give? How should we deliver them (intranasal or intravenous)? In addition, we’re also developing new, inexpensive, and easy to use imaging tools to allow clinicians the ability to readily identify brain damage in preterm infants.